Chromologic LLC

Chromologic LLC, a minority-owned, American Indian-owned, and Subcontinent Asian American-owned small business based in Monrovia, California, develops advanced biomedical and medical-device technologies for the federal government as a prime contractor (96% of awards) under SBIR and STTR programs and federal research grants. The company operates predominantly under total small business set-asides across research and development contracts spanning radiation medical countermeasures, portable diagnostic devices, CRISPR-based assays, and microRNA biomarker development.

Chromologic's customer concentration reflects its research-and-development posture. The top five funding agencies account for 48% of award volume and 76% of combined potential value, led by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (one award, $25.2 million combined potential value) and NIAID (15 awards, $24.7 million). Army Medical Command (19 awards, $10.7 million), the Defense Health Agency (8 awards, $5.9 million), and the DOD Missile Defense Agency (4 awards, $4.5 million) round out the top five. NAICS coding confirms the research orientation: 41 awards under R&D in Physical, Engineering, and Life Sciences (non-Biotechnology), 36 under R&D in Physical, Engineering, and Life Sciences (non-Nanotechnology), and 7 under R&D in Biotechnology. Recent representative prime work includes a $4.5 million cost-plus-fixed-fee definitive contract from NIAID (July 2026 through June 2029) for development of radiation and nuclear medical countermeasures, biodosimetry devices, and an engineered probiotic therapeutic (LR-IFN-Beta) for gastrointestinal acute radiation syndrome mitigation; a $1.5 million Phase II SBIR award from NIAID (September 2025 through September 2028) for development of a CRISPR-based assay for portable tropical infection diagnosis (CAPTIN-D); and a $1.3 million Phase II SBIR award from the Defense Health Agency (September 2025 through January 2028) for a ceramic membrane-based portable oxygen generator for forward surgical teams. Chromologic also received a $5.52 million cost-plus-fixed-fee NIAID contract (July 2023 through June 2027) for development of MIDOS, a microRNA biodosimeter, and a $2.05 million Phase II SBIR award from the Naval Air Warfare Center (June 2022 through March 2027).

Across the federal grant portfolio, Chromologic operates as a prime recipient under NIH programs centered on radiation-injury prevention and rapid infectious-disease diagnostics. Recent grants include a $533,384 NIH Cooperative Agreement (September 2025 through August 2030) to validate the MIDOS assay for predicting radiation-induced lung injury, performed in collaboration with the Greater Los Angeles Veterans Administration Medical Center and UCLA; a $306,469 CDC Project Grant (September 2025 through September 2026) for development of the Wearable Heat-Related Injury Risk Analysis (WHERA) System under the Investigations and Technical Assistance program (CFDA 93.283); and a Cooperative Agreement from NIH (December 2024 through November 2029) for investigation of mechanisms of hematopoietic acute radiation syndrome mitigation using an engineered probiotic LR-IFN-Beta. Chromologic also received a National Eye Institute Project Grant (June 2022 through August 2027) for development of the EYE-PATH system, a next-generation sequencing-based metagenomic diagnostic platform for ocular infections, performed in partnership with the University of Washington.

Award activity has remained steady over recent years—eight awards in 2022, seven in 2023 and 2024, seven in 2025, and three in 2026 to date—with eleven awards (combined potential value $16.4 million) reaching ultimate completion inside the next twenty-four months and facing recompete in that window. SCI-reported invoiced revenue on federal service contracts carried $2.1 million in FY2022 (7.8 FTEs) and $1.9 million in FY2023 (5.2 FTEs), with no SCI-reportable invoicing in FY2024 or FY2025; on these contracts, government-paid rates ran median around $126.19 per hour, with senior labor pricing through approximately $300 per hour. Chromologic self-performed all SCI-reported hours with zero subcontractor involvement. In its limited subcontracting role, Chromologic delivers radiological and nuclear medical countermeasure product development support (LR-hIFN-β and LR-mIFN-β manufacture, material, testing, and reporting) under Alpha Omega Biotechnology Services LLC as prime (two sub awards, May 2025). Chromologic also performed subaward work under UCLA on microRNA biomarker identification for radiation exposure (May 2024) and an optical coherence tomography cell-monitoring project (April 2025).